Pharmacy/Drug Stores

Issue Code: PHA

Share:𝕏LinkedInFacebook
🤖

AI Overview

Pharmacy/Drug Stores is one of the 79 issue categories tracked under the Lobbying Disclosure Act. With $262.2M in total lobbying spend across 9,053 filings, it ranks among the significantly lobbied policy areas in Washington. The money flowing into this issue reflects how much is at stake for the industries involved.

$262.2M
Total Lobbying Spend
9,053
Filings
50
Top Clients

Spending by Year

YearSpendingFilings
2018$26.3M1,052
2019$29.3M1,134
2020$32.0M1,161
2021$32.9M1,053
2022$36.8M1,159
2023$35.0M1,198
2024$30.3M1,055
2025$39.6M1,241

Biggest Spenders

#ClientSpending
1Pharmaceutical Research and Manufacturers of America$8.2M
2Walgreen Co.$7.1M
3Cvs Health$5.0M
4Endo USA, INC., a Mallinckrodt-endo Company$4.2M
5PHRMA$3.4M
6Viatris INC$3.3M
7Cigna Corporation$3.1M
8Consumer Healthcare Products Association$3.1M
9Genentech, INC.$2.9M
10Pharmaceutical Care Management Association (Pcma)$2.9M
11Healthcare Distribution Alliance (Healthcare Distribution Managment Assn.)$2.9M
12Unitedhealth Group, INC.$2.9M
13Community Oncology Alliance$2.8M
14Healthcare Distribution Alliance$2.8M
15Eli Lilly and Company$2.7M
16National Association of Chain Drug Stores$2.6M
17The Campaign for Sustainable Rx Pricing$2.6M
18Neurocrine Biosciences, INC.$2.6M
19America's Health Insurance Plans$2.5M
20Travere Therapeutics$2.5M
21American Veterinary Medical Association$2.4M
22Alkermes, INC.$2.3M
23Pharmaceutical Industry Labor-management Association$2.1M
24Cvs Health INC$2.1M
25Alliance for Rural Hospital Access$2.0M

Top Firms

Mehlman Consulting, INC.$14.6M
Todd Strategy Group$11.6M
Rubicon Advisors, LLC$9.0M
Kountoupes Denham Carr & Reid, LLC$8.9M
BGR Government Affairs$8.8M
Marshall & Popp, LLC$7.4M
Tarplin, Downs & Young, LLC$6.9M
Foley & Lardner LLP$6.8M
Brownstein Hyatt Farber Schreck, LLP$5.8M
Forbes-tate$5.7M
Farragut Partners LLP$4.9M
Akin Gump Strauss Hauer & Feld$4.2M
Invariant LLC$3.6M
Ricchetti Incorporated$3.6M
Penn Avenue Partners$3.5M

What They Lobby For

  • Drug shortages and FDA approval. USTR acceptance.
  • drug pricing, drug supply chain, opioid abuse epidemic, Medicare Part D
  • Controlled Substance act improvements. Opioid overdose death reduction. Alprazolam rescheduling.
  • Federal government relations service, strategy development and implementation relating to companys status of FDA action on NDA for oral testosterone.
  • Issues related to health insurance and prescription drug pricing.
  • Time-Temperature Indicators for Pharmaceuticals; and Drug Quality and Security Act
  • Issues relating to the regulations around drug manufacturing.
  • Drug FDA Approval: CAM2038
  • Federal government relations service, strategy development and implementation relating to status of FDAs action with regards to the companys NDA.
  • Federal government relations service, strategy development and implementation relating to regenerative medicine products.

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.